Greetings. Welcome to the Leidos First Quarter 2020 Earnings Call. At this time, all participants will be in listen-only mode. A brief question-and-answer session will follow the formal presentation. Please note this conference is being recorded. At this time, I will turn the conference over to Peter Berl, Investor Relations. Mr. Berl, you may begin.

Thank you, Rob and good morning, everyone. I would like to welcome you to our first quarter 2020 earnings conference call. Joining me today are Roger Krone, our Chairman and CEO; Jim Reagan, our Chief Financial Officer and other members of the Leidos management team. Today, we will discuss our results for the quarter ending April 3, 2020. Roger will lead off the call with notable highlights from the quarter as well as comments on the market environment and our Company's strategy. Jim will follow with a discussion of our financial performance and our guidance expectations. After these remarks from Roger and Jim, we will open the call for your questions. Today's discussion contains Forward-Looking Statements based on the environment as we currently see it, and as such does include risks and uncertainties. Please refer to our press release for more information on the specific Risk Factors that could cause actual results to differ materially. Finally, during the call, we will discuss GAAP and non-GAAP financial measures. A reconciliation between the two is included in the press release that we issued this morning and is also available in the presentation slides. The press release and presentation as well as supplementary financial information file are provided on the Investor Relations section of our website at ir.leidos.com. With that I will turn the call over to Roger Krone.

Thank you all for joining us this morning for our first quarter 2020 earnings conference call. These are challenging times for all of us. And I sincerely hope that each of you and your families are both safe and healthy. First Quarter results demonstrated the resiliency of our business, as evidenced by strong pro forma organic revenue growth across all business segments, significant bookings and a new record backlog position. While the COVID-19 pandemic presented some late quarter headwinds, we are confident that the critical nature of our work, coupled with our early business contingency planning will mitigate any long-term impacts. In the quarter, the business delivered revenue of 2.89 billion, reflecting 12.1% growth from the prior year, adjusting for acquisitions and divestiture activity, the pro forma organic growth rate was 8.2% demonstrating the continued conversion of our successful business development campaigns to revenues. We delivered non-GAAP diluted earnings per share of $1.19 up 5.3% from the prior year. We generated $372 million of cash from operations and ended the quarter with a strong cash balance of $445 million. Net bookings of 5.5 billion yielded a book-to-bill of 1.9 for the quarter, a significant achievement compared to our historical pattern. With several recent favorable protests and resolutions on single award IDIQs, we expect additional bookings, as incremental task orders are awarded against these vehicles later in the year. Adjusted EBITDA margin of 9.3% was lower than prior year. Primary factors were late quarter COVID-19 headwinds and a charge related to an international receivable. The impact of COVID-19 in the first quarter was approximately 15 million in revenue and 9 million in non-GAAP operating income. As discussed during the fourth quarter earnings call, we closed the Dynetics acquisition back on January 31st. The integration activities are progressing as planned on a pro forma basis, Dynetics delivered approximately 30% top-line growth in the quarter, demonstrating that businesses strength in fast growing strategic areas such as hypersonics, space exploration in unmanned systems. Just last week, Dynetics was awarded one of three prime contracts by NASA under the Artemis program to develop a human landing system through the preliminary design phase. Our contract consists of two phases, a 10-month base period for preliminary design valued north of 250 million, followed by a down-select to two contractors for a four year option period to build and send a lander to the moon. This win will be captured in our second quarter bookings and backlog. Following the theme of M&A activity, yesterday we announced the closing of the acquisition of L3Harris' security detection and automation business. We are excited about what this acquisition means for our future in a high growth ever expanding global security market. While COVID-19 is causing a temporary impact on airlines and airport traffic volumes, the lower traffic scenarios are actually causing many airports to consider pulling in upgrades and maintenance activity during this unseasonably slow traffic period. After careful review of first quarter results and the business pipeline including recent discussions with key customers and prospects, we remain confident that this transaction will create significant value for Leidos, our customers and our shareholders. We welcomed the 1200 employees to the Leidos family and look forward to updating you on our integration and synergy activities over time. We continue to expect this acquisition to be accretive to revenue growth, adjusted EBITDA margins and earnings this year. Jim will provide more details on this later in his remarks. As of today reflecting both acquisitions, our estimated net leverage ratio is 3.7, as we have stated consistently in the past. Our target net leverage ratio is 3.0 and as such, our capital deployment philosophy will prioritize debt reduction until we approach that level while sustaining our quarterly dividend and funding important capital and R&D investments to continue to drive growth. From an organic growth perspective, I would like to highlight a couple of notable programs from the quarter that reflects the successful defense of two protests in our defense solutions segment and one in our civil segment. In all three cases, Leidos is the incumbent. The first is the Global Solutions Management Operations or GSM-O contract where we continue to manage a series of networks and computer systems that serve as the backbone of the department of defense commanding control systems. This 10-year single award IDIQ contract has a ceiling value of 6.5 billion if all options are exercised. Note that the GSM-O II contract has yet to contribute materially to our backlog and will do so over time as new task orders are issued. Second, the protest of the Department of Energy's Hanford Mission Essential Services contract was also resolved in our favor. The 10-year single award IDIQ contract has an approximate value of four billion if all options are exercised. Finally, the Air Force National Capital Region or ASMCR Information Technology Service Support contract was also successfully defended. Under this five year, 450 million single award IDIQ contract, we will continue to provide a full range of support and services to our nation's command and control systems and IT support for thousands of users. During the COVID-19 crisis we are enabling teleworking capabilities through hardware software and cloud-based service deployments. To support our business' continuing growth, our talent acquisition efforts continue to attract and hire 100 or more new employees each week. We hired over 1800 in the first quarter. This result is made possible by our recruiting and on-boarding programs, which adopted a number of virtual practices well before the current COVID-19 crisis. Turning now to COVID-19. This global pandemic is affecting us all. At Leidos, we have been carefully managing the impacts to our people, our community, our business partners and our customers. We have implemented changes to our business rhythms to maximize telework where possible and minimize risk to our employees. We have revisited and improved certain healthcare benefits for our employees to minimize the burden on them and their families during the crisis. I am proud to report that the whole Leidos family from employees up to the board have stepped up to offer aid in their communities through generous donations. Since the start of the outbreak, employees have donated nearly $400,000 to the Leidos Relief Foundation to assist their colleagues who have been directly impacted by the virus. Last week, our board of directors unanimously approved a reduction in director compensation for the current year. As a result of this decision, the Company will contribute $0.5 million dollars to the Relief Foundation. Additionally, I have donated my salary to the Relief Foundation during the pandemic. Externally the Company has contributed more than $250,000 with a commitment to match up to an additional $1 million of employee donations to the all of us combat Coronavirus campaign created by the U.S. Centers for Disease Control and Prevention Foundation. Our customers recognize the critical nature of the services that we perform and the overwhelming majority of our work remains without impact. We have identified approximately $270 million of revenue or about 2% of our total for 2020 that is expected to be impacted by COVID-19, much of which we expect to recover in 2021. The passage of the CAREs Act does provide some relief for us in our industry peers. However, since this specific implementation is left to the discretion of contracting officers, we are not allowed to build fee on certain contracts where the workforce is kept at home in a ready state. This is the cause for the majority of margin reduction in the defense solutions segment. To minimize business impacts and to continue to deliver innovative solutions in a cost-efficient manner, we have implemented a number of cost cutting measures across the organization. These actions include reduced discretionary spending, an indirect hiring freeze of non-essential open positions, and mandatory time off on alternating Fridays for indirect staff. In a few minor areas, where we have seen reduced business volumes, furloughs have been implemented. Beyond this is worth highlighting that Leidos supports many customers who are in the news today for their efforts on addressing the pandemic, including NIH, CDC, FDA and others. We are unique among our peers in the breadth of our health capabilities and have been engaged with all of these customers and more to leverage our capabilities to directly help combat the pandemic. First, on behalf of the NIH is National Cancer Institute, our subsidiary Leidos Biomedical Research staffs and operates the Frederick National Laboratory for Cancer Research, which is dedicated exclusively to the biomedical sciences. Frederick National Laboratory's scientists have been working directly with the NIH to facilitate an international therapeutic trial of remdesivir in COVID-19 patients. Second, the Frederick National Laboratory scientists are also conducting research to identify genetic determinants of virus susceptibility and outcomes, hopefully leading to better therapeutics and medicines to combat the virus. In other parts of our health business, we have been exploring opportunities to develop and offer virtual care solutions, which support the complete pandemic pathway from patient intake and pre-screening to virtual visits with staff physicians via remote monitoring within the hospital or other care environments. While these are challenging times for all of us, the mission essential nature of our work, the additional protective measures in the CARES Act, and the significant actions we are taking as a company provide a strong foundation for our business as we manage headwinds entering the second quarter. Jim will give more details on our revised guidance, but in short, after reflecting both the expected COVID-19 impacts, as well as offsets from the inclusion of the L3Harris Security acquisition, our revised guidance enables us to maintain our cash flow from operations guidance at the same level as before at $1 billion or higher, while decreasing revenue by 1% and earnings per share by 6%, at the midpoint of our range. From a macro perspective, fiscal year 2021’s budget levels for both defense and non-defense spending are set under the bipartisan budget agreement. And Congress does not plan to change those levels, despite the unprecedented spending increases being enacted to offset the economic impact of COVID-19. Consequently, there should be more certainty in the budget process this year, even though we expect fiscal year 2021 to start under a continuing resolution due to the November elections. Longer term, however, deficit pressures could impact both defense and domestic spending levels, potentially starting as early as fiscal year 2023. But again, the 18 to 24 months delay from budget dollars to outlay dollars provides us with runway before we are potentially faced with that dynamic. Further, DoD's unobligated balance of over 100 billion could mitigate the impact of any future cuts to budget authority in the first one to two years of a downturn scenario. Finally, in closing, I would like to comment briefly on the transition in our Investor Relations team. Peter Berl was recently appointed as Head of our IIR team and brings over 25 years of experience across numerous financial departments within Lockheed Martin and Leidos where he most recently served as CFO of our Health Group. Peter succeeds Kelly Hernandez, who after six years as our IR lead was recently named the new CFO of our Civil Group. I would like to thank Kelly for her many contributions in her prior role. I know she will be a great asset to the Civil Group. With that, I will turn the call over to Jim Reagan our Chief Financial Officer for more details on our first quarter results and our full-year outlook.

Thank you Roger and thanks for everyone joining us on the call today. I will start by sharing some highlights from the quarter and then I will provide some color on what we see as the potential impacts on COVID-19 for the remainder of the year in the context of our updated guidance. Beginning with revenue we are pleased with our strong start to the year. First quarter revenues grew 12.1% over the prior year and 8.2% organically continuing our growth momentum into 2020. The increase in revenue was driven by high levels of on-contract growth and increased contributions from new programs that ramped up during the quarter. These increases were offset by a slowdown in programs related to COVID-19 which caused an approximately $50 million impact to the quarter's revenue. Excluding this first quarter, organic growth would have been 10% over the prior year period. Adjusted EBITDA margins of 9.3% declined 80 basis points from the prior year quarter. The declines were characterized by two events. The first was what I would broadly characterize as COVID-19 related, particularly impacting our Defense Solutions segment program's ability to perform coupled with the inability to recognize fees on the maintenance of ready state labor. This impact is approximately $9 million to adjusted EBITDA. The second item is an $8 million charge related to an international receivable. After adjusting for these discrete items, adjusted EBITDA margins would have been more in-line with historic company levels. Non-GAAP diluted EPS for the quarter increased $0.06 cents over the prior year to $1.19 primarily reflecting a lower non-GAAP effective tax rate and lower share count. Operating cash flows of $372 million were above seasonal norms and reflect the continued diligent management of our working capital as well as the implementation of the accounts receivable monetization facility, which we discussed previously, which contributed nearly $140 million in the quarter. We had another strong quarter in business development resulting in bookings of over $5.5 billion bringing our book-to-bill for the quarter to 1.9x and a record ending backlog position of $28.3 billion. This outstanding backlog number reflects the successfully defended protests on the Hanford and AFNCR contracts as well as our continued success in competing for new programs and take away opportunities. Before I get into segment results, I would like to point out that effective at the start of 2020 we reassigned several programs from the Civil Reportable Segment to the Defense Solutions Reportable Segment to better align segment operations with the customers they serve. That impact was that programs worth a total of about 1 billion of annual revenue moved out of Civil and into the Defense Solution Segment. The 2019 financials have been recast to reflect the new structure for a year-over-year comparison, and have been provided to you in the supplementary financials file on our website. Now for an overview of our segment results. Defense Solutions Segment revenue grew 14.4% on a year-over-year basis, reflecting 5.7% organic growth and two months of contribution from Dynetics. On a pro forma basis for the full quarter, Dynetics experienced approximately 30% growth compared to the prior year period. These strong growth rates take into account COVID-19 impacts that affected some of our intelligence programs in the latter part of the first quarter. We expect these programs to return to their normal run rates during the third quarter. Non-GAAP operating margins of 6.8% in our Defense Solutions Segment are uncharacteristically low, declining 120 basis points from the prior year quarter. The current quarter margins reflect $7 million associated with programs impacted by COVID-19, an increase in indirect expenditures and a reserve for a potential $8 million receivables write down on an international program. Defense Solutions booked over $1 billion of net awards, resulting in a book-to-bill of 0.8x in the quarter and 1.6x on a trailing 12 month basis. The recent successful resolution of the protest on the GSM-O II contracts has not yet impacted these metrics due to our booking methodology. However, as we receive task orders on this IDIQ contract later in the year, the backlog will reflect those new bookings. In our civil segment, revenues grew 5% from the prior year quarter and 6.9% organically. This growth was driven by the increased contribution from the ramp up of new programs and volume growth on our existing programs. This growth was partially offset by the sale of our commercial cyber business last year. Non-GAAP operating margins in the Civil Segment were strong at 10.9%. The prior year's margin of 12.4% reflected a number of non-recurring items which resulted in a higher than usual in margin write ups combined with higher volume in our Security and Transportation Systems business. While the first quarter of 2020 saw lower product volumes and mix, we look forward to driving more value in this higher margin segment with the addition of the L3Harris Security Detection and Automation businesses. Civil generated nearly $4 billion in net bookings in the quarter for a book-to-bill of 6.1x. This was largely driven by the positive impact from the successful resolution of the protest on the Hanford contract. Finally, turning to our health segment. Revenues grew 14.5% over the prior year period and 18.5% organically after adjusting for the divestiture of the commercial staff augmentation business. This strong organic growth was due primarily to increased program volumes and expansion of scope on our existing programs. Non-GAAP operating income for the health segment grew 360 basis points to 15.5% from the prior year quarter due to a shift in program mix. Our health segment saw approximately $250 million in bookings in the quarter driving a book-to-bill of 0.5x with a trailing 12 months book-to-build of 0.9x. And now on to the remainder of the year. We are updating our 2020 guidance for revenue adjusted EBITDA margin and non-GAAP diluted EPS to include the addition of the L3Harris Security Detection and Automation businesses and the expected impacts to our business from COVID-19. We are adjusting our revenue guidance to a range of $12.5 billion to $12.9 billion. The updated range reflects 13% to 16% growth over the prior year. This range includes approximately $290 million in revenue contribution from the security detection and automation businesses offset by approximately $370 million of expected impact from COVID-19 and other associated market uncertainties. Note that we expect our COVID impacted programs to ramp back up to our normalized run rates during the second quarter, resuming full run rate in the fourth quarter and then continuing unimpacted into 2021. We also anticipate that we will start to make up some of the lost revenue from Q1 and Q2 during the latter half of 2020 and into early 2021 as employees are able to return to previously closed customer work locations. With the abatement of the COVID-19 impacts beyond the fourth quarter, combined with the strength of our backlog and recent awards position, we are confident that we will achieve high single-digit organic growth in 2021 with margins at or above our 10% adjusted EBITDA margin long-term target. In terms of margins, we expect adjusted EBITDA margins of 9.8% to 10% for this year. The primary drivers of the 20 basis point reduction from the prior range included an estimated value of approximately 30 basis points associated with COVID-19 offset by the approximate 10 basis point increase from the inclusion of the security detection and automation revenues at accretive margins. Specifically, COVID-19 is impactful from a margin perspective in a few different ways. First, the revenue headwinds we are currently experiencing in our higher margin generating businesses. We expect to begin increasing our volumes back to normal run rates in these portfolios beginning in the second quarter. Second, some of our customers are only reimbursing costs and not fees associated with maintaining ready state labor on certain programs, impacting margins on some intelligence programs within the Defense Solutions Segment. Third, as mentioned earlier, we expect to begin ramping back to our historical run rate and margin mix across the enterprise beginning in the second quarter of 2020. Our expectation is that we will be at normalized margins in the fourth quarter and continuing into 2021. These revenue and margin changes result in an updated non-GAAP diluted EPS guidance range of $5 to $5.30. Our non-GAAP diluted EPS guidance range includes modest accretion from the SG&A transaction, and we expect the accretion from the transaction to increase beyond 2020 as we undertake integration activities and begin to realize revenue and cost synergies. As Roger indicated, our guidance for operating cash flows remains unchanged at $1 billion or more for the year. As a reminder, our capital deployment efforts are focused on debt reduction, rather than share repurchases until we approach our target net leverage ratio of 3.0x, which we expect to do by the end of the first quarter of 2021. Let me provide you with a couple of additional comments to help you with modeling. We expect net interest expense for the full-year of 197 million inclusive of the L3Harris Security Detection and Automation transaction. We also expect a slightly lower non-GAAP tax rate in 2020 of 22%. Before we turn it over for questions, I would like to mention that for the third consecutive year, Leidos has been recognized as one of the 2020 World's Most Ethical Companies by the Ethisphere Institute, a global leader in defining and advancing the standards of ethical business practices. Leidos is one of only 132 honorees from 21 countries and 51 industries to receive this recognition and this award would not have been possible without each and every one of our employees committing to do what is right every day. With that, I will turn the call over to Rob, so we can take some questions.

Thank you. Our first question today comes from Jon Raviv with City Group. Please go ahead with your questions.

Hey, thanks. Good morning everyone. Roger, you talked about some of these items of there is demand disruption and then potentially some areas there could be demand disruption. Can you parse between those two dynamics? It sounds like it is mostly disruption, but you did mention some potential shortfalls that could be with us for longer?

Okay. I'm trying to understand your question. Let me take a shot and if I don't get it. I think we were pretty clear both Jim and I that we don't see significant long-term impact as a result of COVID-19, which is what I think your question was. Most what we saw a little bit in Q1, but mostly in the month of April, except for the 3610 fee, which we will never get back because we are only being reimbursed for costs and not fee. We see almost all of that revenue moving to the right and we will either pick it up in third quarter or fourth quarter or in a roll into 2021. For instance, as you all know, we do a lot of work at hospitals, right? Our Defense Health program is installing the new millennium software in hospitals. Those hospitals are now being used for COVID-19 even those at military bases. As such, we are not getting access to the hospital right now. And so we are slowing down our deployment, but those deployments will still occur. They just move to the right by a quarter or so. And so in some programs we will pick back up. In fact, it is already starting to gain momentum again and should be fully back in third or fourth quarter. So John, I don't believe I said that we saw permanent impairment of our business. If you heard that in my comments, then I apologize. Clearly, we have seen impact in the month of April, but the vast majority of our impact is either the earnings we lose on 3610 or revenue and earnings that have been delayed. Back to you Jon.

Thanks, Roger. I didn't mean to imply that you said, I just want to make sure we are perfectly clear on the disruption idea here. But I was getting at though and a real quick follow-up here is just, you did bring up the idea that going forward, how maybe in 2023, 2024, 2025 let's say, deficit starts to become more of an issue, discretionary spending could be pressured. I mean, you are a big business, but you are also operating in a big market. How do you think about the Company positioning for what that long-term spending environment could be? Because it is still going to be mission essential spending. But how do you position for those priorities essentially?

Yes, Jon we are really pleased with how we have repositioned the business over the last five years to be in parts of the market that we think are more resilient to what will be eventually a cyclical flattening of government spending. We have moved into mission essential digital transformation areas and have diversified from our concentration in DoD to where we now have essentially our four markets and defense until health and civil infrastructures. So we are really pleased with how we have restructured the company and how we have positioned ourselves for the markets going forward. And if the Department of Defense slows in growth, I think we will see a lot of civil infrastructure projects. How we do inspection at airports is going to change with social distancing. And we are well positioned to take advantage of shifts and spending in that direction.

Thank you.

Next question is from the line of Matt Akers with Barclays. Please proceed with your question.

Hey, good morning, guys. Thanks for the question. I wonder if you could comment a little bit on the security detection business. I know, Roger, I think you mentioned you may be seeing some demands for forward during this fiscal period. But I mean, how much of that business you think is tied to sort of air travel run-rate and kind of just seeing sort of an unprecedented downturn there. And so how much of it is sort of that versus kind of longer cycle stuff that you have for booked already?

Yes, over the period of signing to closing. We have gone out and touched all of our traditional long-term customers and the new long-term customers that come to us by way of the L3Harris acquisition. We really wanted to understand what their capital spending plans were and what their view of technology was. This is funded through TSA. There are some markets where the inspection function is funded by ticket surcharges, and it is a mix as you go country-to-country. What we heard across the board was movement in new technologies, social distancing at checkpoints, CT scanning, and the addition of biometrics, which very few airport checkpoints have today whether that be facial recognition, temperature scanning. What has gotten us excited is I think this is going to spawn a recapitalization of checkpoints. We were talking to one customer that said we put ultraviolet lights in the tray return conveyor so that we could sanitize the tray as it comes back around and is presented to the next traveler. All of that is capital investments. All of that really plays well with the L3Harris business that we have gotten. Of course, our traditional business was very strong in ports and borders. This only accelerates the need to do inspection at the ports and borders as we want to have control of the border, but we want to be able to tell you not only who is coming across, but now there are some aspects about do they have a temperature, things like that. So we are very, very excited about the L3Harris business, back when we signed the deal in early February, and the world events have only made us more excited.

Great, thanks. That is helpful. And I guess just one other on MHS GENESIS there have been a couple of press reports that there may be some delays in that program. Are those impacting you? And what sort of the run rate that you guys are at on that program long-term?

As I made my comment to Jon, because those hospitals and even the ones that military bases have been dedicated to COVID-19, or at least put in a ready state. So we have had to do more work off-prem to get ready for deployments. We are doing some other work on behalf of DHA as well with our team. But there has been an impact that we have seen slowing of our deployment. Maybe I will let Jim comment.

Yes. As you know there was supposed to be a peak in the deployment activity late this year early next. And now with the rescheduling, it is clear that peak has been pushed out into 2021 as we re-jigger our scheduled to accommodate the use of the hospitals for COVID-19 patients.

Okay. Got it. Thank you.

Thanks Matt.

Thanks, Matt.

Thank you. Our next question comes from the line of Robert Spingarn with Credit Suisse. Please go with your questions.

Hi, good morning.

Hey, good morning, Rob.

Good morning, Rob.

Rob, you talked about the work that you do with NIH that directly touches on the pursuit of a cure or therapeutic for COVID-19. Could you talk about the materiality of that revenue where it stands now? And could that be a meaningful needle mover as we move forward? And then really, as a follow-up to that higher level, how should the market think about Leidos given that you have a healthcare segment? And just the long-term ramifications of the federal response to this disease?

Okay. Let me start with the easy one. The work we do at the Frederick National Laboratory for cancer research is part of our FFRDC support contract and although we believe it is very, very important to the country, and it is a great past performance call for us. It has never been a material set of numbers for a $12 billion, $13 billion company. So it is just not - and it has to do with the way that contract for FFRDC are structured, and how we book. That being said, the work we believe is highly important and it provides credibility for us across our healthcare segment. And longer term we like being in the healthcare sector. We view that as a significant growth market for us. It is, as you all have seen, our highest margin market, which says our customers value what we bring to the market there. We continue to invest and grow in that marketplace. And your question about the federal response. I will make this statement, and I’m really proud of what the organizations that we work with have done in response to the pandemic. This is unprecedented and unpredicted and every organization that we work with, whether they are at NIH or NCI or frankly, our DoD and Intel customers have all leaned forward. We are doing virtual customer meetings by phone. We are doing Zoom chats and across the board, there are a lot of people who are critical out there is not us. We are thrilled with all the hard work that all of our customers have done to try to keep our workforce employed and paid and to combat the pandemic and to take care of their employees and our employees.

I guess where I was going with that Roger was, once we are through this, if they set up some kind of a federal pandemic office to try and prepare differently, let's say for next time. How much of an advantage does Leidos have versus the competition, given that you are already in the healthcare IT arena?

Let's see, we think we have a significant advantage. Part of why we do FFRDC work is to have knowledge of the environment and how therapeutics are created and how vaccines are created. Rob, as you may know, we are heavily involved in the Ebola vaccine and the worldwide effort to eradicate Ebola off the face of the planet. Although it doesn't generate significant profit the way some of our other large programs do, it gives us great credibility as we pivot to support what very well may be a federal response - a permanent federal response to future potential pandemics.

Thank you, Roger.

Thank you.

Next questions come from the line of Cai von Rumohr with Cowen. Please proceed with your question.

Yes, thank you very much. So Roger, you talked about $270 million of COVID impact. And yet the guide has $370 million, which would imply about $100 million for other market certainties. Could you give us some color on what those other market uncertainties are? And then of the $270 of COVID-related, walk us through some more specifics like the dim-some impact and some sense of the quarterly pattern. Because it would suggest the COVID impacts can be bigger in the second quarter than the first year.

Yes Cai, let me get started on that and I will let Jim pick up what I don't talk about. So the $270 is that from a bottoms up, we can tie directly to COVID-19. So 3610 CAREs act, slow down on dim-some. When we touch guidance, we sit back and go, Okay, what are the unknown unknowns? Although it hasn't happened yet, we think some of the procurements are going to slow down, and there is just going to be a little bit more drag on the business writ large. When we touch guidance, we felt it was prudent to put another $100 million of revenue headwind in our guidance, and it is not specific. And I can't go into the additional, the $270, we can almost go contract-by-contract and Jim may touch on the major pieces there. The additional $100 for us is, I actually thought we were going to get an NDA this year. And now I don't think we will. I think we will be in a continuing resolution. Our forecasts are seeing a continued growing federal budgets and operating in a normal way. Now I don't think that is going to happen, I think procurement will slow down, the things will take longer, meetings take an extra week or two, there will be no travel. We wanted to put in another $100 million of headwind to get us to a midpoint, which was indeed our 50/50. A little bit of a quarter-by-quarter, Cai we don't guide by quarter. That being said, April must be the worst month, given what we all have been through. We have already seen states start to reopen here in Virginia, the governor is talking about opening next week and non-essential. We think that May will be better and June will be even better. If you are starting to face - now you know our first quarter, there is just no doubt that second quarter is going to be the quarter that is the most impacted. We expect, as Jim said in his comments, to be fully recovered, or maybe be better than by the fourth quarter. Jim do you want to add some color?

Yes. Just a couple more comments. Rob, you characterized it exactly that the $100 million is the piece of our revision that does not have any specific contracts tied to it, but it is that out of what we - Cai as you know, we try to be pretty conservative in how we guide and it was we thought the prudent thing to do. Some color on a couple of contracts we mentioned dim-sum. There is also, for example, we support the National Science Foundation in Antarctica. The Antarctic is the one continent that has no COVID-19 today and they want to keep it that way. They have slowed down the level of activity that we are going to have down on the ice for the balance of the year and so that is - now there are some big programs down there that we are going to manage. That is what is impacting into 2021, like a lot of these impacts. A couple of contracts have a lot of fixed costs, and they are also fixed unit price. That downdraft is going to be temporary in the second quarter, impacting revenue and margin in Q2. Our customers that procure those products and services have already contacted us about their restart plans. We are working with them closely to begin re-ramping back in the second quarter. We expect that we will be in much better shape there in the third.

Very helpful. So you mentioned protests, could you update us on the next gen protests, and also the UNH Defense Health takeaway win?

Yes, well you know, right now, we are in the throes of finishing and have recently finished all the back and forth and responses on the engine protest. We continue to expect that that will be concluded in the second quarter. That would result in a booking in Q2. Do you have another one in mind, Cai? I'm sorry.

Just UNH Defense Health. Take away win?

Yes, we call that our RHRP. Right. That is in protest as well. So two more months from where we are.

Yes. That should also be resolved by the end of the second quarter Cai, and we will have something to say about that on our next call as well.

Thanks so much.

Okay.

Our next question comes from the line of Edward Caso with Wells Fargo. Please proceed with your questions.

Hi, good morning.

Good morning Ed.

Good morning.

I was wondering how much of your revenue guidance is a function of requests for equitable adjustments, if that is a meaningful factor that you need to recapture?

Ed, this is Jim. The REAs right now are in the forecast very conservatively like zero. It is not our habit to include those in revenue projections mainly because the timing of resolution of those is pretty difficult. We have had a number of customers, I can think of one customer in the Health Group and a couple of customers in the Defense segment that have invited us to prepare a request for equitable adjustment for things like the fee on COVID standby labor pre-March 27th, which isn't provided specifically in the CAREs Act. Our customers do understand that there is some significant loss of profit. The pursuit and successful closure of REAs, if it happens this year, would result in some upside to the numbers that we have out there.

Great. Can you also talk a little bit about your clients' behavior on award activity and whether you are seeing bridges and extensions in the current environment? Thanks.

Ed, thanks. I will start on that. To-date they have awarded pretty much on time And almost to our surprise, and like the human lander program out of NASA really was right on schedule. That being said, part of the $100 million that we add into our revenue guidance is conservatism on our part that may not continue as we go throughout the summer. Just the RFP process where maybe we used to do oral face-to-face and now we are going to have to do orals by video. We just think that is going to take longer. But as through today, we have not really seen anything that I would call an appreciable delay. In fact, on our L3Harris deal or Hart Scott, we got early termination. The government is up and operating and things are moving forward.

Thank you.

The next question is from the line of Seth Seifman with JP Morgan. Please proceed with your questions.

Thanks very much and good morning. I was curious on the airport security acquisition, there were the presentation that you guys did when the deal was announced back in January I think, when you look at that now, should we still be thinking about the same types of numbers for around 2020 and the out years? Or kind of when you look at things after the cause?

Yes, thanks for the question Seth. When we took a look at this business, most before COVID and really very recently, in doing our due diligence update, we saw that the business was up through the beginning of COVID. The business was outperforming our own projections and pipeline and backlog as we recently looked at it still looks good. As Roger mentioned, we had an opportunity to touch-base with many of their major customers. We were pleased that they are continuing with much of their plans. In fact, we are thinking about how to reconfigure some of the systems that the L3Harris business has already sold to accommodate the need for more lanes, for example, because of the need for slower testing, as airline customers go through security dimensions by the way of example. Now with that said, there will undoubtedly be some slowdown in the revenue and just because of the inability in the short run to get some of the work done, but it hasn't changed our view of what the order backlog of the business is. Those provisions have been incorporated into our guide for that business for the rest of the year.

Yes Seth. I just want to add, if you were going to take a word out of what we have heard, the word touchless is what we are hearing from customers about the transit of passengers through security checkpoints. Every customer we have talked to has said we have been doing this in a highly personal, highly contacted environment. Going forward, we don't want to put, for instance in the U.S. our TSA agents at risk, and we don't want to contact the traveling public. If you recall your experience back when we all flew, depending upon what happens, you were touched, and especially if you get a pat down, you might be touched three or four times through the checkpoint, and that is just going to be unacceptable going forward. The TSA agents not going to want to hold your driver's license, right? They are going to want another way of verifying who you are. You're going to put your material in a bin, before you put material in another bin, you want to know that bin is sanitized, right? If you need to go through a secondary, you want to do a secondary in a way where a TSA agent doesn't actually have to make contact with you. That means CT at the checkpoint. There is a lot of great application of technology to the checkpoint of the future and again, we are excited about the opportunity to grow the business that we bought.

Okay. Thanks that is all I have.

Next question is from the line of Sheila Kahyaoglu with Jefferies. Please proceed with your question.

Hi. Good morning, Roger and Jim and thank you for the time. Roger, I wanted to follow-up on Bob's question with regarding the healthcare opportunity. Not only on health care, but maybe IT infrastructure just given government employees are also working from home. Kind of where are we in terms of timing with these opportunities? When do they emerge? Are we in step one in terms of tracking and tracing? Maybe Can you talk about that?

Let me start with the easiest and that which we have already seen a positive impact. Sheila, as you know we provide IT infrastructure and digital transformation for a whole host of government customers from CMS to the Pentagon. We are the telework provider for a significant part of the government. In fact, I will recount a story a agency director elected to work at home. That director had never worked at home before. We are the infrastructure for that particular agency. We facilitated that individual's work at home, configured a laptop, and made sure that he had enough bandwidth at home, and provided user support. That has been going on across our IT transformation contracts. That is immediate. It is not really in our guide. We don't really know how it is going to come down to the bottom line, but we are seeing that across the board and even more so in the health world. Telemedicine is going to be a big deal. We view that both in the short-term and the long-term. I think, John's question was where or Rob’s was really focused on, we used to have a pandemic working group and that team just gone away. We all know that is going to come back. We have seen a global viral outbreak every seven to 10 years. We know this is not here - there will be a COVID-25. We expect that the federal government and organizations like NIH and NIAID will mobilize to put in a better response capability. We think for us, that is a significant growth opportunity.

Okay, thank you. And then maybe one follow-up on defense. When we add back that international receivable margins are still around the low 7%. So it implies a bit of a ramp. What is going on in terms of profitability in that segment?

Yes, Sheila the profitability in the Defense Group while we did have that unusual item, we had to record. If you take a look back in Q4, you might recall that we had a big write up on a couple of programs in Q4. We keep thinking of that as being a business that should be running longer term at eight-ish or a little north of eight.

Okay. Alright. Thank you very much.

Thank you.

Thanks Sheila.

Thank you. At this time, we have reached the end of our question and answer session and I will hand the call back to Peter Berl for closing comments.

Thank you, Rob. Thank you all for your time this morning and for your interest in Leidos. I look forward to updating you again soon. Have a great day.

This will conclude today's conference. You may disconnect your lines this time. Thank you for your participation.